Andrew Secor (United States of America)

University of Washington Department of Global Health

Presenter of 1 Presentation

 Conference Calendar
Clinical Research / Prophylactic Vaccines – Clinical Aspects ePoster

ALTERNATIVE DOSING SCHEDULES FOR HPV VACCINES AMONG GIRLS AND YOUNG WOMEN: A SYSTEMATIC REVIEW AND META-ANALYSIS (ID 266)

Session Date
07/21/2020
Session Time
10:00 - 17:00
Room
ePoster
Session Type
Poster Viewing - 20-24 July
Session Name
Clinical Research / Prophylactic Vaccines – Clinical Aspects
Lecture Time
10:03 - 10:04
Presenter
Authors

Abstract

Introduction

Three licensed HPV vaccines are approved for 2- or 3-dose schedules: 0, 6 months or 0, 1-2, 6 months. Alternative dosing schedules, particularly single dose and extended intervals between doses (>=12 months), are being considered to address vaccine shortages or operationalize flexibility.

Methods

We searched PUBMED/MEDLINE for publications reporting anti-HPV-16 and -18 ELISA data as geometric mean titers (GMT) following administration of one of the licensed HPV vaccines (2vHPV, 4vHPV, and 9vHPV) to females ages 9-26 years. GMT ratios and confidence intervals (CIs) comparing alternative to standard schedules were calculated using mixed effects meta-regression controlling for baseline HPV status and disaggregated by vaccine, subtype, time point, and age group (9-14 and 15-26 years). Non-inferiority was defined as the lower bound of the 95% CI for the GMT ratio being greater than 0.5.

Results

Our search returned 2,464 studies, of which 24 were included in data analyses. Comparing extended interval to standard schedules (Table 1), at one month post last dose and 36 months post first dose the 2vHPV vaccine showed non-inferiority for HPV-18 but not HPV-16. The 4vHPV vaccine showed non-inferiority for both subtypes at all time points, except for one month post last dose for HPV-16. The 9vHPV vaccine demonstrated non-inferiority for both subtypes at one month post last dose. For single dose (Table 2), data was only available for 2vHPV and 4vHPV, which did not meet criteria for non-inferiority for either subtype at all time points and age groups compared.

ipvc figure 1.png

ipvc figure 2.png

Conclusions

When evaluated against standard schedules, although robust immunogenicity was demonstrated across all multi-dose groups, non-inferiority of extended interval dosing was mixed across vaccines, subtypes, and time points. Single dose did not meet criteria for non-inferiority in any comparisons. Sparse data limited the number of possible comparisons, and further research is warranted.

Hide